Suraksha Diagnostics Q1 FY27 PAT Surges 40% to ₹12.8 Crore on Revenue Growth
Suraksha Diagnostic Limited reported a 40% year-on-year increase in Q1 FY27 Profit After Tax to ₹12.8 crore. Total income grew 21% to ₹88.7 crore, and EBITDA rose 28% to ₹31.5 crore. The company expanded its network and saw strong growth in its genomics business. Patient volumes increased by 12.1% and test volumes by 8.9%.
The announcement details significant financial growth (40% PAT increase) and operational expansion for the current quarter, which is material information for investors and stakeholders.
The company reported strong year-on-year growth in key financial metrics like PAT, EBITDA, and total income, along with operational highlights and positive commentary from management, indicating a favorable financial performance.
Suraksha Diagnostic Limited announced its unaudited financial results for the quarter ended 30 June 2026, reporting a strong performance with Profit After Tax (PAT) growing by 40% year-on-year to ₹12.8 crore (₹128 million) and EBITDA increasing by 28% year-on-year to ₹31.5 crore (₹315 million). The company's total income for the quarter rose by 21% year-on-year to ₹88.7 crore (₹887 million), with an improved EBITDA margin of 36.0% compared to 34.0% in the same quarter last year.
Mrs. Ritu Mittal, Joint Managing Director & CEO, commented that Suraksha started FY27 on a strong note, driven by healthy growth in both volumes and realisations. The quarter saw significant growth in patient and test volumes, alongside improved realisation growth. The company continued its network expansion by commissioning one hub and three spoke centres, aligning with its strategy to build clusters and increase density. Suraksha Genomics also demonstrated strong growth, with a 136% year-on-year revenue increase in Q1 FY27, marking its fifth consecutive quarter of sequential growth.
Operationally, total tests increased by 8.9% year-on-year to 2.10 million, and total patients grew by 12.1% year-on-year to 0.38 million. The average revenue per test saw a 10.6% increase year-on-year to ₹418, and the average revenue per patient increased by 10.5% to ₹2,321.
The company's registered office is located in Kolkata, West Bengal. Suraksha Diagnostic Limited is the largest integrated diagnostic chain in East India, with a presence in West Bengal, Bihar, and Assam. Its central reference laboratory is accredited by the College of American Pathologists, and several laboratories hold NABL accreditation, with advanced diagnostic centres accredited by NABH.
What to do with a filing like this
Suraksha Diagnostic Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Suraksha Diagnostic Limited. Read the original for the full detail.